Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis

Haematologica

Volumn 81, Issue 5, 1996, Pages 428-433

  Molica, Stefano ^a   Levato, Domenico ^a   Dell'Olio, Matteo ^b   Matera, Rossella ^b   Minervini, Marta ^b   Dattilo, Angela ^a   Carotenuto, Mario ^b   Musto, Pellegrino ^b  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

B CLL; Prognosis; sCD23

Indexed keywords

CD23 ANTIGEN;

ADULT; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; CHRONIC DISEASE; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL LYMPHOCYTE; PROGNOSIS;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, IGE; TUMOR MARKERS, BIOLOGICAL;

EID: 0030324331     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rai KR, Sawitsky A, Cronkite EP, Chanana ED, Levy RM, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219-34.
2. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48:198-206.
3. Rozman C, Montserrat E, Rodriguez-Fernandez JM, et al. Bone marrow histologic pattern. The best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64:642-8.
4. Rozman C, Montserrat E, Feliu E, et al. Prognosis of chronic lymphocytic leukemia: a multivariate analysis of 150 cases. Blood 1982; 59:1001-5.
5. Mauro FR, De Rossi G, Burgio VL, et al. Prognostic value of bone marrow histology in chronic lymphocytic leukemia. A study of 335 untreated cases of a single institution. Haematologica 1994; 79:334-41.
6. Montserrat E, Sanchez-Bisonò G, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of clinical significance. Br J Haematol 1986; 62:567-75.
7. Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60:2712-6.
8. Vallespi T, Montserrat E, Sanz MA. Chronic lymphocytic leukemia: prognostic value of lymphocytic morphological subtypes. A multivariate analysis in 146 patients. Br J Haematol 1991; 77:478-85.
9. Juliusson G, Oscier DY, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by chromosomal abnormalities. N Engl J Med 1990; 323:720-4.
10. Keating MJ, Lerner S, Kantarajian H, Freireich EJ, O'Brien S. The serum β2-microglobulin (β2M) level is more powerful than stage in predicting response and survival of chronic lymphocytic leukemia (CLL). Blood 1995; 86 (Suppl. 1): 606a.
11. Sarfati M, Bron D, Lagneaux L, Fonteyn L, Frost H, Delespesse G. Elevation of IgE-bindings factors in chronic lymphocytic leukemia. Blood 1988; 71:94-8.
12. Beguin Y, Lampertz S, De Groote D, Igot D, Malaise M, Fillet G. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia. Leukemia 1993; 7:2019-24.
13. Vinante F, Vassanelli A, Zanotti R, et al. Circulating levels of soluble CD23 reflect clinical and biological features of leukemic B-cell chronic lymphoproliferative disorders. Int J Clin Lab Res 1995; 34:189-94.
14. Reinisch W, Willheim M, Hilgarth M. et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 1994; 12:2146-52.
15. Merle-Beral H, Chevret S, Biron G, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1995; 86 (Suppl.1):606a.
16. Desablens B, Capiod JC, Goullieux V, Fuentes V, Garidi R, Claisse JF. Prognostic value of serie levels of soluble CD25 and CD23 receptors in B-CLL. Reports on 109 patients. Br J Haematol 1996; 93 (suppl. 2):28a.
17. Dine G, Culioli B, Rehn Y, Brahimi S. Importance of soluble serum CD23 (sCD23) in the follow-up of B-CLL patients. Br J Haematol 1996; 93(suppl. 2):112a.
18. International Workshop on CLL. Recommendations for diagnosis, staging, and response criteria. Ann Intern Med 1989; 110:236-8.
19. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8:1640-5.
20. Kaplan EL, Meier P. Non parametric estimation of incomplete observations. J Am Stat Ass 1958; 53:457-62.
21. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II, Analyses and examples. Br J Cancer 1977; 35:1-39.
22. Molica S, Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991; 78:895-9.
23. Geisler CH, Larsen JK, Hansen NE, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991; 78:1795-802.
24. Rozman C, Montserrat E. Current concepts. Chronic lymphocytic leukemia. N Engl J Med 1995; 333:1052-7.
25. Fournier S, Rubio M, Delespesse G, Sarfati M. Role for low-affinity receptor for IgE (CD23) in normal and leukemic B-cell proliferation. Blood 1994; 84:1881-6.
26. Molica S, De Rossi G. Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update. Haematologica 1995; 80:176-93.